115 related articles for article (PubMed ID: 34841595)
1. Identification of glycogene-based prognostic signature and validation of B3GNT7 as a potential biomarker and therapeutic target in breast cancer.
Wang X; Wang Y; Chen X; He Y; Zhou X; Jiao S; Zhu Z; Wu C; Bao J
J Cancer Res Clin Oncol; 2023 Dec; 149(19):16957-16969. PubMed ID: 37740763
[TBL] [Abstract][Full Text] [Related]
2. Prognostic gene expression signatures of breast cancer are lacking a sensible biological meaning.
Manjang K; Tripathi S; Yli-Harja O; Dehmer M; Glazko G; Emmert-Streib F
Sci Rep; 2021 Jan; 11(1):156. PubMed ID: 33420139
[TBL] [Abstract][Full Text] [Related]
3. DNA copy number motifs are strong and independent predictors of survival in breast cancer.
Pladsen AV; Nilsen G; Rueda OM; Aure MR; Borgan Ø; Liestøl K; Vitelli V; Frigessi A; Langerød A; Mathelier A; ; Engebråten O; Kristensen V; Wedge DC; Van Loo P; Caldas C; Børresen-Dale AL; Russnes HG; Lingjærde OC
Commun Biol; 2020 Apr; 3(1):153. PubMed ID: 32242091
[TBL] [Abstract][Full Text] [Related]
4. Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test.
Mittempergher L; Delahaye LJ; Witteveen AT; Snel MH; Mee S; Chan BY; Dreezen C; Besseling N; Luiten EJ;
Transl Oncol; 2020 Apr; 13(4):100756. PubMed ID: 32208353
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling in luminal breast cancer.
Gluz O; Hofmann D; Würstlein R; Liedtke C; Nitz U; Harbeck N
Breast Care (Basel); 2013 Dec; 8(6):414-22. PubMed ID: 24550749
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in Cancer Detection, Diagnosis, and Prognosis.
Das S; Dey MK; Devireddy R; Gartia MR
Sensors (Basel); 2023 Dec; 24(1):. PubMed ID: 38202898
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers in Breast Cancer: An Old Story with a New End.
Neves Rebello Alves L; Dummer Meira D; Poppe Merigueti L; Correia Casotti M; do Prado Ventorim D; Ferreira Figueiredo Almeida J; Pereira de Sousa V; Cindra Sant'Ana M; Gonçalves Coutinho da Cruz R; Santos Louro L; Mendonça Santana G; Erik Santos Louro T; Evangelista Salazar R; Ribeiro Campos da Silva D; Stefani Siqueira Zetum A; Silva Dos Reis Trabach R; Imbroisi Valle Errera F; de Paula F; de Vargas Wolfgramm Dos Santos E; Fagundes de Carvalho E; Drumond Louro I
Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510269
[TBL] [Abstract][Full Text] [Related]
8. Predictive genomic tools in disease stratification and targeted prevention: a recent update in personalized therapy advancements.
Jain N; Nagaich U; Pandey M; Chellappan DK; Dua K
EPMA J; 2022 Dec; 13(4):561-580. PubMed ID: 36505888
[TBL] [Abstract][Full Text] [Related]
9. Unlocking phenotypic plasticity provides novel insights for immunity and personalized therapy in lung adenocarcinoma.
Wang F; Du H; Li B; Luo Z; Zhu L
Front Genet; 2022; 13():941567. PubMed ID: 36147496
[No Abstract] [Full Text] [Related]
10. Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.
Whitworth P; Beitsch PD; Pellicane JV; Baron PL; Lee LA; Dul CL; Nash CH; Murray MK; Richards PD; Gittleman M; Budway R; Rahman RL; Kelemen P; Dooley WC; Rock DT; Cowan K; Lesnikoski BA; Barone JL; Ashikari AY; Dupree B; Wang S; Menicucci AR; Yoder EB; Finn C; Corcoran K; Blumencranz LE; Audeh W;
Ann Surg Oncol; 2022 Apr; 29(7):4141-52. PubMed ID: 35378634
[TBL] [Abstract][Full Text] [Related]
11. Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.
Bayraktar S; Royce M; Stork-Sloots L; de Snoo F; Glück S
Med Oncol; 2014 Oct; 31(10):163. PubMed ID: 25186065
[TBL] [Abstract][Full Text] [Related]
12. Molecular signatures in breast cancer.
Lal S; McCart Reed AE; de Luca XM; Simpson PT
Methods; 2017 Dec; 131():135-146. PubMed ID: 28669865
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
14. MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients.
Haan JC; Bhaskaran R; Ellappalayam A; Bijl Y; Griffioen CJ; Lujinovic E; Audeh WM; Penault-Llorca F; Mittempergher L; Glas AM
Genes Chromosomes Cancer; 2022 Mar; 61(3):148-160. PubMed ID: 34841595
[TBL] [Abstract][Full Text] [Related]
15. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Wuerstlein R; Kates R; Gluz O; Grischke EM; Schem C; Thill M; Hasmueller S; Köhler A; Otremba B; Griesinger F; Schindlbeck C; Trojan A; Otto F; Knauer M; Pusch R; Harbeck N;
Breast Cancer Res Treat; 2019 Jun; 175(2):389-399. PubMed ID: 30796651
[TBL] [Abstract][Full Text] [Related]
16. The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer.
Exner R; Bago-Horvath Z; Bartsch R; Mittlboeck M; Retèl VP; Fitzal F; Rudas M; Singer C; Pfeiler G; Gnant M; Jakesz R; Dubsky P
Br J Cancer; 2014 Aug; 111(5):837-42. PubMed ID: 25003667
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
